Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-08-04

Clinical Trial Update: R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of tipifarnib (R115777) in recurrent or metastatic non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZARNESTRA

Snippet

Sponsor: Mayo Clinic | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED